A Phase IV, prospective, open-label, uncontrolled, European Study in patients with neovascular Age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching From intravitreal Aflibercept to RanIbizumab 0.5mg: the SAFARI study
Basic data for this project
Type of project: Individual project
Duration at the University of Münster: since 01/04/2015
Description
Keywords: Klinische Studie; SAFARI
Funding identifier: CRFB002AGB17
Funder / funding scheme:
- Novartis Pharma GmbH
Project management at the University of Münster
| Eter, Nicole | Clinic for Ophthalmology |
Applicants from the University of Münster
| Eter, Nicole | Clinic for Ophthalmology |